Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer

BJU International

Volumn 101, Issue 9, 2008, Pages 1096-1100

  Fujii, Yasuhisa ^a,b   Yonese, Junji ^a   Kawakami, Satoru ^a   Yamamoto, Shinya ^a   Okubo, Yuhei ^a   Fukui, Iwao ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

LHRH agonist; Prostate cancer; Testosterone levels

Indexed keywords

GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CASTRATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG MECHANISM; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SKIN MANIFESTATION; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TESTOSTERONE; TREATMENT OUTCOME;

EID: 41849086998     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07374.x     Document Type: Article

References (19)

1. Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000 132 : 566 77
2. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000 164 : 726 9
3. Smith MR, McGovern FJ. Gonadotropin-releasing hormone agonist failure in a man with prostate cancer. J Urol 2001 166 : 211
4. Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006 49 : 54 8
5. Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int 1998 60 (Suppl. 2 18 24
6. Khan MS, O'Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 1998 60 : 33 40
7. Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 2003 92 : 226 31
8. Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol 1996 30 (Suppl. 1 7 14
9. Sharifi R, Bruskewitz RC, Gittleman MC, Graham SD Jr, Hudson PB, Stein B. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther 1996 18 : 647 57
10. Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res 2007 13 : 241 5
11. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006 295 : 1549 55
12. Koupparis AJ. Re: Olav Erich Yri, Trine Bjoro, Sophie D. Fossa. Failure to achieve castration levels in patients using leupoprolide acetate in locally advanced prostate cancer. Eur Urol 2006; 49 : 54 58. Eur Urol 2006 50 : 626 7
13. Ogan K, Berger M, Ball R. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma. J Urol 1998 160 : 497 8
14. Matsuda T, Hiura Y, Oguchi N, Muguruma K, Murota T, Kawakita M. Failure of a gonadotropin-releasing hormone analogue to lower serume testosterone in patients with prostate cancer. Urology 2002 59 : 296x xii
15. Loblaw DA, Mendelson DS, Talcott JA et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004 22 : 2927 41
16. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000 56 : 1021 4
17. Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 2005 4 : 14 9
18. Soloway MS, Chodak G, Vogelzang NJ et al. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group. Urology 1991 37 : 46 51
19. Oefelein MG. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998 160 : 1685 8